Angiogenesis without functional outcome after mononuclear stem cell transplant in a doxorubicin-induced dilated myocardiopathy murine model

International Journal of Artificial Organs

Volumn 31, Issue 5, 2008, Pages 431-438

  Carvalho, Katherine Athayde Teixeira ^a,b,c   Simeoni, R B ^a   Guarita Souza, L C ^a   Francisco, J C ^a   Abdelwahid, E ^d   Myiague, N I ^a   Chachques, J C ^e   Rivetti, L A ^f   Oliveira, L ^b   Malvezzi, M ^b   Olandoski, M ^a   Gremski, W ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c INSTITUTO DE PESQUISA PELÉ PEQUENO PRÍNCIPE   (Brazil)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f Santa Casa de São Paulo and Hospital Santa Isabel   (Brazil)

Author keywords

Bone marrow stem cells; Dilated myocardiopathy; Doxorubicin; Echocardiographic

Indexed keywords

CYTOLOGY; RATS;

ANGIOGENESIS; BONE MARROW STEM CELLS; CELL THERAPY; CELL TRANSPLANTS; DILATED MYOCARDIOPATHY; DOXORUBICIN; ECHOCARDIOGRAPHIC; LEFT VENTRICULAR EJECTION FRACTION; STEM CELL THERAPY; STEM-CELL;

STEM CELLS;

DOXORUBICIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CELL VIABILITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; MALE; MONONUCLEAR CELL; NONHUMAN; OUTCOME ASSESSMENT; RAT; STAINING;

EID: 47249145563     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100509     Document Type: Article

References (28)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
2. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998; 40: 426-32.
3. Calabresi F, Di Lauro L, Marolla P, Curcio CG, Paoletti G, Calabró A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, et al. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus Ionidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. Semin Oncol 1991; 18: 66-72.
4. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.
5. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77-86.
6. Bachur NR, Gee MV, Friedman RD. Nuclear catalyzed antibiotic free radical formation. Cancer Res 1982; 42: 1078-81.
7. Chachques JC, Salanson-Lajos C, Lajos P, Shafy A, Alshamry A, Carpentier A. Cellular cardiomyoplasty for myocardial regeneration. Asian Cardiovasc Thorac Ann 2005; 13: 287-96.
8. Kotamraju S, Konorev EA, Joseph J, Kalyanaramam B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585-92.
9. Scorsin M, Hagege AA, Dolizy I, Marotte F, Mirochnik N, Copin H, Barnoux M, le Bert M, Samuel JL, Rappaport L, Menasché P. Can cellular transplantation improve function in doxorubicin-induced heart failure? Circulation 1998; 98: 11151-5; 11155-6.
10. Agbulut O, Menot ML, Li Z, Marotte F, Paulin D, Hagège AA, Chomienne C, Samuel JL, Menasché P. Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. Cardiovasc Res 2003; 58: 451-9.
11. Suzuki K, Murtuza B, Suzuki N, Smolenski RT, Yacoub MH. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 2001; 104: 1213-7.
12. Ishida M, Tomita S, Nakatani T, Fukuhara S, Hamamoto M, Nagaya N, Ohtsu Y, Suga M, Yutani C, Yagihara T, Yamada K, Kitamura S. Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy. J Heart Lung Transplant 2004; 23: 436-45.
13. Zhang J, Li GS, Li GC, Zhou Q, Li WQ, Xu HX. Autologous mesenchymal stem cells transplantation in adriamycin-induced cardiomyopathy. Chin Med J (Engl) 2005; 118: 73-6.
14. Tomita S, Ishida M, Nakatani T, Fukuhara S, Hisashi Y, Ohtsu Y, Suga M, Yutani C, Yagihara T, Yamada K, Kitamura S. Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J Heart Lung Transplant 2004; 23: 577-84.
15. Carvalho KA, Guarita-Souza LC, Rebelatto CL, Senegaglia AC, Hansen P, Mendonça JG, Cury CC, Francisco JC, Brofman PR. Could the coculture of skeletal myoblasts and mesenchymal stem cells be a solution for postinfarction myocardial scar? Transplant Proc 2004; 36: 991-2.
16. Guarita-Souza LC, Carvalho KA, Rebelatto C, Senegaglia A, Hansen P, Furuta M, Miyague N, Francisco JC, Olandoski M, Faria-Neto JR, Oliveira SA, Brofman PR. Cell transplantation: differential effects of myoblasts and mesenchymal stem cells. Int J Cardiol 2006; 111 : 423-9.
17. Carvalho KA, Guarita-Souza LC, Hansen P, Rebelatto CL, Senegaglia AC, Miyague N, Olandoski M, Francisco JC, Furuta M, Gremski W. Cell transplantation after coculture of skeletal myoblasts and mesenchymal stem cells in the regeneration of the myocardium scar: an experimental study in rats. Transplant Proc 2006; 38: 1596-602.
18. Menasché P. Cell transplantation in myocardium. Ann Thorac Surg 2003; 75: 20-8.
19. Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Hervé P, Etievent JP, Kantelip JP. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003; 108 (Suppl 1): 11253-8.
20. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
21. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-8.
22. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schümichen C, Nienaber CA, Freund M, Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45-6.
23. Yang J, Zhou W, Zheng W, Ma Y, Lin L, Tang T, Liu J, Yu J, Zhou X, Hu J. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 2007; 107: 17-29.
24. Verfaillie CM. Adult stem cells: assessing the case for pluripotency. Trends Cell Biol 2002; 12: 502-8.
25. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1g. Scand J Clin Lab Invest 1968; 97: 77-89.
26. Bland, J.M, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8: 135-60.
27. Saito T, Kuang JQ, Bittira B, Al-Khaldi A, Chiu RC. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002; 74: 19-24.
28. Li RK, Mickle DA, Weisel RD, Rao V, Jia ZQ. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001; 72: 1957-63.